

Editorial

Open Access

Immunogenic Cell Death and Emission of Damps: Calreticulin and ATP

Dmitri V Krysko^{1,2*}

¹Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium ²Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium

Abbreviations: ATP: Adenosine Triphosphate; CRT: Calreticulin; DAMP: Damage-Associated Molecular Pattern; MYD88; Myeloid Differentiation Primary Response Gene 88; NLR: The Nucleotide-Binding Oligomerization Domain (NOD)-Like Receptor; PRR: Pattern-Recognition Receptor; RLR: RIG-I-Like Receptor; TLR: Toll-Like Receptor

The 'danger theory' was first proposed by Polly Matzinger in 1994. This theory states that the immune system can distinguish self from non-self and dangerous from innocuous signals [1]. This theory has become widely accepted in recent years, especially with the formulation of immunogenic cell death (ICD) concept [2]. Immunogenic characteristics of ICD are mediated mainly by molecules called 'Damage-Associated Molecular Patterns' (DAMPs). These are intracellular molecules normally hidden within live cells, but they acquire immunostimulatory properties upon exposure/release/ secretion by damaged/dying cells.

It was recently reported that only certain agents (e.g. anthracyclines, y-irradiation and hypericin based photodynamic therapy) induce active emission of DAMPs by dying apoptotic cells, and this property determines the efficacy of anti-cancer therapy in the experimental tumor prophylactic vaccination model [3-5]. These studies have shown that surface exposure of calreticulin (CRT), a soluble protein normally located in the lumen of the endoplasmic reticulum, on tumor cells undergoing ICD in response to certain chemotherapeutics (e.g. anthracyclines) facilities their engulfment by dendritic cells (DCs). This leads to tumor-antigen presentation and tumor-specific cytotoxic-T lymphocyte (CTL) responses [3]. It is important to stress that the molecular signaling pathways involved in CRT exposure are strongly dependent on the ICD inducer [4,5]. Another DAMP shown to be actively secreted from cells undergoing ICD is ATP [5,6]. Secretion of ATP, which occurs very early during apoptosis, is also tightly regulated by molecular program(s) [5].

Upon their exposure or release by dying cells, DAMPs interact with membrane-bound or vesicular pattern-recognition receptors (PRRs), including Toll-like receptors (TLRs), purinergic receptors, NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs) [7,8]. For example, it has been shown that extracellular ATP released from cells undergoing ICD activates purinergic P2X7 receptors on DCs. This activates the NALP3–ASC–inflammasome and drives the secretion of IL-1 β , which is required for the polarization of interferon- γ (IFN- γ)-producing CD8+ T cells and for the immune response to tumor cells [9]. We also recently demonstrated that the TLR-2/TLR-9-MyD88 signaling pathways have a central role in initiating the acute inflammatory response to cells undergoing ICD [10].

Substantial progress has been made over the past few years in identifying the DAMPs exposed/released/secreted during ICD and the molecular mechanisms of their emission and recognition by the innate and adaptive immune systems. Indeed, nanoparticles and their applications in biomedicine and medicine has become an extensive area of research [11]. It is important to analyze whether nanopartciles act as DAMPs, whether they can be designed with unique immunomodulatory properties (dependent on size, shape, surface charge and solubility), and if they can instigate different immunological responses. These immunomodulatory properties might be specific for a precise physical type of engineered nanoparticle, and further studies are required to identify and analyze nanoparticle-associated molecular patterns (NAMPs) [12]. Since nanoparticles are also designed to target tumors *in vivo* and are intended for use as therapeutic drug carriers [11], it will be important to analyze whether drugs delivered in nanoparticles will have increased (or changed) immunogenic potential in terms of induction of ICD and emission of DAMPs.

Acknowledgments

I thank Dr A Bredan for editing the manuscript. This work was supported by project grants from the Fund for Scientific Research Flanders (FWO-Vlaanderen, G.0728.10 and 3G067512 to DVK). DVK is a senior postdoctoral fellow paid by fellowship from FWO-Vlaanderen.

References

- Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
- Zitvogel L, Kepp O, Kroemer G (2010) Decoding cell death signals in inflammation and immunity. Cell 140: 798-804.
- Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
- Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, et al. (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28: 578-590.
- Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, et al. (2012) A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31: 1062-1079.
- Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, et al. (2011) Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334: 1573-1577.
- Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, et al. (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805: 53-71.
- Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, et al. (2011) Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 32: 157-164.
- Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178.

*Corresponding author: Dmitri V Krysko, Ph.D, Department for Molecular Biomedical Research, VIB-Ghent University, Technologiepark 927, B-9052 Ghent (Zwijnaarde), Belgium, Europe, Tel: 32 9 3313723; Fax: +32 9 3313609; E-mail: Dmitri.Krysko@dmbr.ugent.be

Received July 03, 2012; Accepted July 04, 2012; Published July 06, 2012

Citation: Krysko DV (2012) Immunogenic Cell Death and Emission of Damps: Calreticulin and ATP. J Nanomed Biotherapeut Discov 2:e118. doi:10.4172/2155-983X.1000e118

Copyright: © 2012 Krysko DV. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Krysko DV (2012) Immunogenic Cell Death and Emission of Damps: Calreticulin and ATP. J Nanomed Biotherapeut Discov 2:e118. doi:10.4172/2155-983X.1000e118

Page 2 of 2

- Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, et al. (2011) TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicininduced acute inflammation. Cell Death Differ 18: 1316-1325.
- 11. Kim BY, Rutka JT, Chan WC (2010) Nanomedicine. N Engl J Med 363: 2434-2443.
- 12. Fadeel B (2012) Clear and present danger? Swiss Med Wkly 142.

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
 Audio Version of published paper
- Digital articles to share and explore

Special features:

•

- 200 Open Access Journals
- 15,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
 Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/pharma